Myriam Reisch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Myriam Reisch has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Jens Thiel
Division of Rheumatology and Clinical Immunology, Medical University of Graz, Graz, Austria
2 shared publications - Martin Helmut Stradner
Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria
2 shared publications - Anamarija Sutic
Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria
1 shared publication Antonia Greb
Department of Internal Medicine, Hanusch Hospital, Vienna, Austria
1 shared publicationArthur Posch
Managerial Accounting & Control, University of Sustainability – Charlotte Fresenius Privatuniversität, Vienna, Austria
1 shared publication- Bojana Durovic
Immunobiology Laboratory, Department of Biomedicine, University Hospital Basel, Basel, Switzerland
1 shared publication
Latest Publications
- Open Access
Predictors of treatment response in rheumatoid arthritis: a narrative review
Rheumatoid arthritis (RA) is a common autoimmune disease having diverse responses to disease-modifying antirheumatic drugs. Although treat-to-target strategies have improved disease management, therapeutic selection remains largely empirical and a substantial proportion of patients fail to achieve adequate clinical response to their therapies. Therefore, reliable biomarkers capable of predicting treatment response before therapy initiation are urgently needed to guide personalised treatment decisions. Current evidence suggests that multiple categories of biomarkers may contribute to the prediction of treatment responses across different therapeutic agents in RA, including clinical characteristics, serological markers, cytokine profiles, genetic and transcriptomic signatures, immune-cell phenotypes, synovial pathotypes and microbiome features. This review summarises current biomarker strategies for predicting therapeutic response in RA and discusses their potential utility in improving precision medicine. However, most individual biomarkers show limited predictive power, partly due to the complex and dynamic nature of RA pathogenesis. Combining biomarkers from multiple biological dimensions, together with the continued exploration of novel predictive markers, may improve the robustness and accuracy of treatment response prediction in RA.
Open AccessPredictors of treatment response in rheumatoid arthritis: a narrative review
Rheumatoid arthritis (RA) is a common autoimmune disease having diverse responses to disease-modifying antirheumatic drugs. Although treat-to-target strategies have improved disease management, therapeutic selection remains largely empirical and a substantial proportion of patients fail to achieve adequate clinical response to their therapies. Therefore, reliable biomarkers capable of predicting treatment response before therapy initiation are urgently needed to guide personalised treatment decisions. Current evidence suggests that multiple categories of biomarkers may contribute to the prediction of treatment responses across different therapeutic agents in RA, including clinical characteristics, serological markers, cytokine profiles, genetic and transcriptomic signatures, immune-cell phenotypes, synovial pathotypes and microbiome features. This review summarises current biomarker strategies for predicting therapeutic response in RA and discusses their potential utility in improving precision medicine. However, most individual biomarkers show limited predictive power, partly due to the complex and dynamic nature of RA pathogenesis. Combining biomarkers from multiple biological dimensions, together with the continued exploration of novel predictive markers, may improve the robustness and accuracy of treatment response prediction in RA.
- Open Access
- 31 August 2026
- Published by Springer Nature in Zeitschrift für Rheumatologie
- Vol. 85 (7) , 563-574
Polymyalgia rheumatica
Zusammenfassung: Die Polymyalgia rheumatica (PMR) ist eine häufige entzündlich-rheumatische Erkrankung im höheren Lebensalter, die durch bilaterale Schmerzen im Schulter- und Beckengürtel, Morgensteifigkeit sowie systemische Entzündungszeichen charakterisiert ist. Trotz ihrer Häufigkeit bleibt die PMR angesichts diagnostischer Unsicherheiten mit einem breiten Spektrum an Differenzialdiagnosen eine klinische Herausforderung. Zusätzlich erschweren die Überlappung mit der Riesenzellarteriitis sowie die aufgrund wiederholter Rezidive häufig erforderliche langfristige Glukokortikoidtherapie, die mit einem erhöhten Risiko für therapieassoziierte Nebenwirkungen einhergeht, das Management der Erkrankung. Entscheidend für die optimale Versorgung der Betroffenen ist eine frühzeitige Diagnosesicherung, eine strukturierte Patient:innenstratifizierung sowie das Einbeziehen individueller Risikofaktoren in die Therapieentscheidung.
- 31 August 2026
- Published by Springer Nature in Zeitschrift für Rheumatologie
- Vol. 85 (7) , 563-574
Open AccessPolymyalgia rheumatica
Zusammenfassung: Die Polymyalgia rheumatica (PMR) ist eine häufige entzündlich-rheumatische Erkrankung im höheren Lebensalter, die durch bilaterale Schmerzen im Schulter- und Beckengürtel, Morgensteifigkeit sowie systemische Entzündungszeichen charakterisiert ist. Trotz ihrer Häufigkeit bleibt die PMR angesichts diagnostischer Unsicherheiten mit einem breiten Spektrum an Differenzialdiagnosen eine klinische Herausforderung. Zusätzlich erschweren die Überlappung mit der Riesenzellarteriitis sowie die aufgrund wiederholter Rezidive häufig erforderliche langfristige Glukokortikoidtherapie, die mit einem erhöhten Risiko für therapieassoziierte Nebenwirkungen einhergeht, das Management der Erkrankung. Entscheidend für die optimale Versorgung der Betroffenen ist eine frühzeitige Diagnosesicherung, eine strukturierte Patient:innenstratifizierung sowie das Einbeziehen individueller Risikofaktoren in die Therapieentscheidung.
- Open Access
- 4 May 2026
- Published by Springer Nature in Drugs
- Vol. 86 (6) , 909-925
Large Vessel Vasculitis: Recent Advances in Pathophysiology and Targeted Therapies
Large vessel vasculitides (LVV), including giant cell arteritis (GCA) and Takayasu arteritis (TAK), share common features such as inflammation of large sized arteries but differ in several key aspects, including age of onset and pathogenic mechanism. This narrative review gives an update of recent insights into pathogenesis of GCA and TAK, and discusses emerging targeted therapies based on these insights. It highlights omics-based signatures, ULK3 and SLAMF7 in GCA, EGR1 in TAK, alongside genetic and somatic risk factors such as clonal haematopoiesis (DNMT3A/TET2) linked to relapse and ischaemic vision loss in GCA, and the IL6R-p.Asp358Ala variant as a predictor of reduced interleukin (IL)-6 receptor blockade response. Common mechanisms include CD4⁺ T-cell, monocyte/macrophage, and B-cell infiltration with activation of IL-6, JAK/STAT/interferon, and IL-17 pathways. Giant cell arteritis is characterised by GM-CSF-driven macrophages and disrupted programmed cell death (PD)-1/PD-L1 checkpoint regulation, while TAK shows dominance of CD8⁺ T cells and tumour necrosis factor (TNF)-α signalling. Interleukin-6 receptor inhibitors (e.g., tocilizumab) show robust efficacy in GCA but with notable non-responders; the JAK inhibitor upadacitinib demonstrated efficacy in a Phase III study, whereas IL-17 blockade (secukinumab) yielded inconsistent results. In TAK, TNF inhibitors and tocilizumab are comparably effective; early data suggest Janus kinases (JAK) inhibitors promote remission, imaging improvement, and glucocorticoid sparing. Mavrilimumab (GM-CSF receptor blockade) is promising in GCA. Recent studies have increasingly focused on short-term glucocorticoid therapy in combination with biologic agents. Advances in biomarker research, including investigation of the IL-6 receptor and IL-17A gene polymorphisms, may enable more targeted therapeutic strategies.
- 4 May 2026
- Published by Springer Nature in Drugs
- Vol. 86 (6) , 909-925
Open AccessLarge Vessel Vasculitis: Recent Advances in Pathophysiology and Targeted Therapies
Large vessel vasculitides (LVV), including giant cell arteritis (GCA) and Takayasu arteritis (TAK), share common features such as inflammation of large sized arteries but differ in several key aspects, including age of onset and pathogenic mechanism. This narrative review gives an update of recent insights into pathogenesis of GCA and TAK, and discusses emerging targeted therapies based on these insights. It highlights omics-based signatures, ULK3 and SLAMF7 in GCA, EGR1 in TAK, alongside genetic and somatic risk factors such as clonal haematopoiesis (DNMT3A/TET2) linked to relapse and ischaemic vision loss in GCA, and the IL6R-p.Asp358Ala variant as a predictor of reduced interleukin (IL)-6 receptor blockade response. Common mechanisms include CD4⁺ T-cell, monocyte/macrophage, and B-cell infiltration with activation of IL-6, JAK/STAT/interferon, and IL-17 pathways. Giant cell arteritis is characterised by GM-CSF-driven macrophages and disrupted programmed cell death (PD)-1/PD-L1 checkpoint regulation, while TAK shows dominance of CD8⁺ T cells and tumour necrosis factor (TNF)-α signalling. Interleukin-6 receptor inhibitors (e.g., tocilizumab) show robust efficacy in GCA but with notable non-responders; the JAK inhibitor upadacitinib demonstrated efficacy in a Phase III study, whereas IL-17 blockade (secukinumab) yielded inconsistent results. In TAK, TNF inhibitors and tocilizumab are comparably effective; early data suggest Janus kinases (JAK) inhibitors promote remission, imaging improvement, and glucocorticoid sparing. Mavrilimumab (GM-CSF receptor blockade) is promising in GCA. Recent studies have increasingly focused on short-term glucocorticoid therapy in combination with biologic agents. Advances in biomarker research, including investigation of the IL-6 receptor and IL-17A gene polymorphisms, may enable more targeted therapeutic strategies.
- Open Access
- 14 February 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (3) , 47
Azathioprine as maintenance therapy for IgG4-related diseases: a retrospective case series and case-based review of the literature
IgG4-related disease (IgG4-RD) is a rare fibro-inflammatory disorder characterized by progressive fibrosis involving multiple organs and tissues. Clinical manifestations are highly variable, reflecting the organs affected. Oral glucocorticoids (GC) are established as first-line therapy; however, relapse occurs in 15–60% of patients. To reduce relapse risk and GC-related adverse effects, GC-sparing strategies using disease-modifying antirheumatic drugs (DMARDs) may be considered. This study aims to evaluate the efficacy and safety of azathioprine in the management of IgG4-RD and provides an overview of the current literature. This retrospective case series assesses disease activity under azathioprine therapy in patients with IgG4-RD treated at the Medical University of Graz between 2006 and 2024. Patients with a confirmed IgG4-RD diagnosis according to the 2019 ACR/EULAR criteria who received azathioprine following initial GC therapy were included. Ten male patients (mean age at disease onset: 59.4 years) with a mean follow-up of 75.2 months were analyzed. All patients fulfilled the 2019 ACR/EULAR classification criteria. Indications for initiating azathioprine included disease relapse on GC ( n = 3), GC-related adverse effects ( n = 3), and the intention to reduce GC exposure ( n = 7). During azathioprine therapy, three patients (30%) experienced a total of five relapses. Seven patients receiving azathioprine remained in remission throughout the observation period. Adverse events included infections ( n = 2), hematologic abnormalities ( n = 4), and elevated liver enzymes ( n = 1). At last follow-up, five patients (50%) remained on azathioprine, two (20%) had switched to rituximab, one of whom was in remission and off therapy, and three patients (30%) were no longer receiving immunosuppressive treatment (two due to hematologic abnormalities, one by patient request), with no further therapy initiated. Azathioprine represents an appropriate maintenance therapy for IgG4-RD. In cases with relapse under azathioprine, alternative DMARDs, such as CD19- or CD20-targeted therapies, may be more effective.
- 14 February 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (3) , 47
Open AccessAzathioprine as maintenance therapy for IgG4-related diseases: a retrospective case series and case-based review of the literature
IgG4-related disease (IgG4-RD) is a rare fibro-inflammatory disorder characterized by progressive fibrosis involving multiple organs and tissues. Clinical manifestations are highly variable, reflecting the organs affected. Oral glucocorticoids (GC) are established as first-line therapy; however, relapse occurs in 15–60% of patients. To reduce relapse risk and GC-related adverse effects, GC-sparing strategies using disease-modifying antirheumatic drugs (DMARDs) may be considered. This study aims to evaluate the efficacy and safety of azathioprine in the management of IgG4-RD and provides an overview of the current literature. This retrospective case series assesses disease activity under azathioprine therapy in patients with IgG4-RD treated at the Medical University of Graz between 2006 and 2024. Patients with a confirmed IgG4-RD diagnosis according to the 2019 ACR/EULAR criteria who received azathioprine following initial GC therapy were included. Ten male patients (mean age at disease onset: 59.4 years) with a mean follow-up of 75.2 months were analyzed. All patients fulfilled the 2019 ACR/EULAR classification criteria. Indications for initiating azathioprine included disease relapse on GC ( n = 3), GC-related adverse effects ( n = 3), and the intention to reduce GC exposure ( n = 7). During azathioprine therapy, three patients (30%) experienced a total of five relapses. Seven patients receiving azathioprine remained in remission throughout the observation period. Adverse events included infections ( n = 2), hematologic abnormalities ( n = 4), and elevated liver enzymes ( n = 1). At last follow-up, five patients (50%) remained on azathioprine, two (20%) had switched to rituximab, one of whom was in remission and off therapy, and three patients (30%) were no longer receiving immunosuppressive treatment (two due to hematologic abnormalities, one by patient request), with no further therapy initiated. Azathioprine represents an appropriate maintenance therapy for IgG4-RD. In cases with relapse under azathioprine, alternative DMARDs, such as CD19- or CD20-targeted therapies, may be more effective.